Researchers from three universities, including Indiana University, have found that price competition in the generic drug market might be putting more patients at health risk due to a higher number of manufacturing-related product recalls.
The Indianapolis-based health system said it will continue to study possibilities for the land after neighbors objected to plans calling for nine buildings and four parking garages that carried an estimated price tag of $1 billion.
In a letter to the Indiana Department of Workforce Development, the company said “changing business needs require us to reduce operations at this facility.”
The Indianapolis-based drugmaker has been working for years to develop the much-anticipated drug, which some analysts had said might ring up $2 billion a year in sales.
Researchers at Indiana University and the Regenstrief Institute are measuring whether a virtual walk on the beach could help prevent cognitive issues faced by patients who spend time on a mechanical ventilation machine in the intensive care unit.
An Indianapolis-based company that makes handheld medical testing devices plans to move its 150 employees to a new headquarters in Boone County, where it will hire an additional 50 to 70 workers.
New therapies that could cure diseases caused by defective genes will get quicker approval from U.S. regulators, part of an effort by the Food and Drug Administration to keep pace with one of biotechnology’s fastest-growing fields.
President Donald Trump’s interest in the bill stems from a push by Vice President Mike Pence, who championed the initiative when he was governor of Indiana.
Brian Griffin, the leader of Anthem’s new PBM, IngenioRx, quit on May 8 with no warning to become CEO of Michigan-based Diplomat Pharmacy. Now Anthem is scrambling to adjust.
President Donald Trump is set to unveil his long-awaited plan for reducing drug prices after more than a year of bold promises to tackle pharmacy costs that are squeezing millions of Americans.
The Indianapolis-based pharmaceutical giant said it plans to acquire ARMO BioSciences Inc., which is working on treatments that activate the immune system of cancer patients to recognize and eradicate tumors.
The money is designed to further the work of Dr. Burcin Ekser and his team, who are working to print three-dimensional pig liver tissue from genetically engineered pig liver cells.
The ads for the metastatic breast cancer drug Verzenio show women in their 50s and 60s looking resolute and indomitable, surrounded by smiling friends and family.
Shares in Athenahealth Inc. surged the most since 2016 after activist investor Elliott Management Corp. bid to acquire the medical company for $160 a share.
A five-year, $7 million program is led and supported by a coalition of local health institutions, including Eli Lilly and Co., Fairbanks School of Public Health and Eskenazi Health. It is based on a model that Lilly has used in other countries.
The Indianapolis pharmaceutical giant is evaluating whether to keep the division, which makes animal-health products, or sell it or take it public. An analyst said it might fetch $16 billion.
Indianapolis-based Eli Lilly and Co. on Tuesday reported quarterly revenue and adjusted earnings that exceeded analyst forecasts.
The plaintiffs—Planned Parenthood of Indiana and Kentucky, the American Civil Liberties Union and the ACLU of Indiana—called the measure "a cruel intimidation tactic."
The Health and Human Services funding is among $485 million recently awarded nationwide to combat heroin and opioid abuse.
Cigna Corp. confirmed that its proposed $54 billion acquisition of Express Scripts Holding Co. will be reviewed by the U.S. Department of Justice, which has raised the bar for approving deals that don’t combine direct competitors.
